Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Restrictive New Rules May Limit Access To Velcade For Some Newly Diagnosed Multiple Myeloma Patients In The UK

Home/Restrictive New Rules May Limit Access To Velcade For Some Newly Diagnosed Multiple Myeloma Patients In The UK

Restrictive New Rules May Limit Access To Velcade For Some Newly Diagnosed Multiple Myeloma Patients In The UK

Here is an English press release from the company which distributes Velcade in the UK.  Looks like the British may be headed in the wrong direction here:

NICE proposes to restrict access to Velcade® (bortezomib)
in newly diagnosed multiple myeloma patients
Janssen-Cilag to challenge NICE recommendation

Janssen-Cilag, High Wycombe, 26 August 2010 – Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma. The company intends to appeal against the Final Appraisal Determination (FAD) which recommends the use of Velcade (bortezomib) in combination with an alkylating agent and a corticosteroid as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate and who are unable to tolerate or have contraindications to thalidomide.[i]

NICE refused wider use of bortezomib in the front line setting on the grounds of cost-effectiveness.

Peter Barnes, Medical Director at Janssen-Cilag UK said,
“Whilst we acknowledge that a small number of newly diagnosed patients may benefit, in this indication the larger proportion of myeloma patients will be denied the chance of treatment with bortezomib if this recommendation becomes guidance. We believe we have demonstrated that bortezomib is a clinically and cost-effective treatment option for this group of newly diagnosed myeloma patients. For this reason we intend to appeal the draft recommendation which would mean that cancer patients in England and Wales would be disadvantaged compared to those in much of Europe, where bortezomib has been widely available in this setting for a number of years.”

It is unclear to me what exactly “will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma.” means.  Who decides which patients will have access and why?  I will follow this story and keep you updated… We have lots of readers “across the pond.”

Feel good and keep smiling!  Pat